← All trials
NCT04940390
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2021
- Primary completion
- Sep 30, 2022
- Completion date
- Oct 31, 2022
- First posted
- Jun 25, 2021
- Last posted
- Nov 1, 2021
- Enrollment
- 1400
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Satsuma Pharmaceuticals, Inc.Lead sponsor
- Satsuma Pharmaceuticals, Inc.Study chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.